Drugs / Myrcene
Myrcene
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05432284 | Jul 2026 → Nov 2027 expected | substance-related disorder | Johns Hopkins University | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04091789 | Sep 2019 → Mar 2020 | dysmenorrhea, migraine disorder, mood disorder | Pure Green | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04451863 Comparator | Dec 2021 → Nov 2025 overdue | substance abuse | University of California, Los Angeles | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Myrcene | “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ |
| Known as | .beta.-geraniolene | ChEMBL registry synonym — accepted as the source's own label CHEMBL455491 ↗ |
| Known as | Beta-Myrcene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05432284 ↗ |
| Known as | FEMA NO. 2762 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455491 ↗ |
| Known as | NSC-406264 | ChEMBL registry synonym — accepted as the source's own label CHEMBL455491 ↗ |
| Modality | Small molecule | — CHEMBL455491 ↗ |
| Route | Other | “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗ |